Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Meningococcal Vaccines Market From 2025 to 2029?

Over the past few years, the meningococcal vaccines industry has seen robust growth. The market value is predicted to rise from $3.89 billion in 2024 to $4.26 billion in 2025, thanks to a compound annual growth rate (CAGR) of 9.3%. The expansion in the historical period was driven by factors such as the prevalence of disease, global travel patterns, the state of healthcare infrastructure, preparedness for epidemics, and the coverage of health insurance.

The market size of meningococcal vaccines is poised for substantial growth in the coming years, with projections noting a growth to “$6.05 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. Reasons driving the growth during this forecasted period include the emergence of new strains, an increase in globalization, rising healthcare investments, health initiatives, and a transforming regulatory environment. Notable trends expected during this forecasted timeframe encompass personalized vaccines, the implementation of digital vaccination records, the advent of gene editing technologies, the development of multi-valent vaccines, and the introduction of subscription-based vaccine models.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Elements Are Contributing To Growth In The Meningococcal Vaccines Market?

The anticipated surge in healthcare spending is predicted to accelerate the growth of the meningococcal vaccine market. Healthcare, in this context, encompasses facilities like residential care establishments, nursing homes, or intermediate care centers for individuals with mental illnesses or mental retardation. The fact that newer vaccine generations tend to be more expensive than their older counterparts is widely debated, particularly in terms of whether the vaccines’ advantages outweigh their costs. Thorough appraisal of both the societal and fiscal benefits of vaccinations has become an essential research aspect in literature that evaluates vaccination. For example, an article by the American Medical Association in May 2022 highlighted that US healthcare expenditures have risen by 9.7%, equating to $4.1 trillion or $12,530 per individual. This growth rate vastly surpasses that of 2019, which was 4.3%. Consequently, the augmentation in healthcare expenses is influencing the upswing in the meningococcal vaccine market.

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

How Are Key Trends Driving Expansion In The Meningococcal Vaccines Industry?

Leading businesses in the meningococcal vaccines market are focusing on creating new vaccines to combat specific serogroups, which, in turn, will amplify their market earnings. Meningococcal vaccines serve as protective measures against infections triggered by certain serogroups of the bacterium Neisseria meningitidis. For instance, Pfizer Inc., a pharmaceutical firm based in the US, obtained FDA approval in October 2023 for their vaccine PENBRAYA. PENBRAYA, being capable of extensive coverage against serogroups, became the most all-inclusive meningococcal vaccine approved in the U.S., providing protection against groups A, B, C, W, and Y. The FDA’s approval was based on compelling Phase 2 and 3 trial results, which demonstrated the vaccine’s comparable immunogenicity to Trumenba + Menveo across all serogroups, along with a favorable safety profile. In September 2022, Pfizer released promising results from a Phase 3 trial, where PENBRAYA outperformed already licensed meningococcal vaccines in terms of safety, tolerability, and immunogenicity.

Who Are The Key Contributors To Growth In The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Which Region Is Projected To Lead The Meningococcal Vaccines Market By 2025?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model